复发性卵巢癌新药PARP抑制剂niraparib  

The novel PARP inhibitor in recurrent ovarian cancer: niraparib

作　　者：何概易南 简晓顺 尹一子 HE Gai-yi-nan;JIAN Xiao-shun;YIN Yi-zi(Affiliated Cancer Hospital ＆ Institute of Guangzhou Medical University,Guangzhou 510095,China)

机构地区：[1]广州医科大学附属肿瘤医院药学部,广州510095

出　　处：《中国新药杂志》2018年第15期1714-1717,共4页Chinese Journal of New Drugs

摘　　要：近年研究表明,聚腺苷二磷酸核糖聚合酶(PARP)抑制剂在乳腺癌易感基因(BRCA)突变的乳腺癌和卵巢癌患者中可明显延长无瘤生存期。2017年3月27日,FDA加快批准PARP抑制剂niraparib用于对铂类药物化疗完全响应或部分响应的上皮卵巢癌、输卵管或原发性腹膜癌的成年复发患者的维持治疗。本文从理化特性、临床前研究和临床研究等方面介绍该首个批准用于卵巢癌维持疗法的PARP抑制剂niraparib,以期为临床医生和卵巢癌患者选择治疗方法提供参考。Recent studies have shown that poly（ADP-ribose） polymerase（PARP） inhibitors significantly prolong the progression-free survival in the patients with breast cancer and ovarian cancer with the breast cancer susceptibility gene（BRCA） mutations. On March 27,2017,FDA accelerated the approval of the PAPR inhibitor niraparib for the maintenance treatment of adult patients with recurrent epithelial ovarian,fallopian tube,or primary peritoneal cancer who were in complete or partial response to platinum-based chemotherapy. In this paper,we introduced niraparib,the first PARP inhibitor for the maintenance therapy of recurrent ovarian cancer,from the aspects of physicochemical properties,preclinical studies and clinical studies,in order to provide reference for doctors and patients with ovarian cancer.

关 键 词：卵巢癌 聚腺苷二磷酸核糖聚合酶 抑制剂 niraparib 

分 类 号：R979.1[医药卫生—药品]